Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease ( CTAD ) Conference

GlobeNewswire
2024.10.31 00:04

Eisai Co., Ltd. and Biogen Inc. presented findings on lecanemab, an anti-amyloid beta antibody for early Alzheimer's disease, at the CTAD Conference. Long-term studies showed that continued treatment with lecanemab resulted in significant cognitive improvements and reduced disease progression risk. A new method for measuring protofibrils in cerebrospinal fluid was developed, revealing a strong correlation with neurodegenerative biomarkers. The data suggest that early initiation of lecanemab treatment may positively impact disease progression in early Alzheimer's patients, with no new safety concerns reported over three years of treatment.

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.